Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 31:2022:8011745.
doi: 10.1155/2022/8011745. eCollection 2022.

Clear Lensectomy with Hydrus Stent in Black and Afro-Latino Patients: A 1-Year Retrospective Study

Daniel Laroche  1   2 , Jessinta Oseni  3 , Gideon Nkrumah  4 , Chester Ng  2
Affiliations

Clear Lensectomy with Hydrus Stent in Black and Afro-Latino Patients: A 1-Year Retrospective Study

Daniel Laroche et al. J Ophthalmol. .

Abstract

Purpose: To determine the efficacy and safety of phacoemulsification, clear lensectomy, and the Hydrus microstent (Ivantis, Inc.) in Black and Afro-Latino glaucoma patients.

Method: This is a retrospective nonrandomized study of 134 Black and Afro-Latino patients who underwent clear lensectomy with Hydrus stent implant for the treatment of glaucoma. For comprehensive analysis, patients were divided into mild, moderate, and advanced glaucoma. The evaluated parameters were reductions in the number of medications, intraocular pressure (IOP), mean deviation on visual field test, and visual acuity.

Results: A total of 134 patients with 1-year follow-up were evaluated. At 1 year, the average number of medications significantly decreased from 2.5 ± 1.4 preoperatively to 0.43 ± 1.04 (p < 0.001) and IOP decreased from 14.4 ± 3.9 to 13.8 ± 3.10 (p=0.16). 110 (82.1%) patients were medication-free at 1 year (n = 57, 83.8% mild glaucoma; n = 37, 92.5% moderate glaucoma; n = 16, 61.5% advanced glaucoma). There was stabilization of mean deviation on the visual field test (baseline, -8.28; 1 year, -8.28; p=1). The most reported adverse effects were transient IOP spike and hyphema (n = 7, 5.2%; n = 3, 2.2%, respectively); both events were self-resolving. No decline in vision or sight-threatening complications were reported at 1 year, and no additional surgeries were required.

Conclusion: This 1-year retrospective study demonstrated the efficacy and safety of clear lensectomy and Hydrus stent implantation in decreasing medication burden while maintaining lower IOP in Black and Afro-Latino glaucoma patients.

PubMed Disclaimer

Conflict of interest statement

Daniel Laroche is a consultant to Ivantis, Aerie, Sight Sciences, Nidek, and Bausch Health. The following authors declare that there are no conflicts of interest regarding the publication of this article: Jessinta Oseni, Gideon Nkrumah, and Chester Ng.

Figures

Figure 1
Figure 1
Hydrus stent inserted into Schlemm's canal.
Figure 2
Figure 2
Aqueous veins visible before balanced saline solution placed through the Hydrus stent.
Figure 3
Figure 3
Blanching of aqueous veins with balanced saline solution through the Hydrus stent.
See this image and copyright information in PMC

References

    1. Racette L., Wilson M. R., Zangwill L. M., Weinreb R. N., Sample P. A. Primary open-angle glaucoma in blacks: a review. Survey of Ophthalmology . 2003;48(3):295–313. doi: 10.1016/s0039-6257(03)00028-6. - DOI - PubMed
    1. Laroche D., Nkrumah G., Ng C. Real-world efficacy of the Hydrus microstent in Black and Afro-Latinx patients with glaucoma: a retrospective study. Therapeutic Advances in Ophthalmology . 2020;12 doi: 10.1177/2515841420964311.251584142096431 - DOI - PMC - PubMed
    1. SooHoo J. R., Seibold L. K., Radcliffe N. M., Kahook M. Y. Minimally invasive glaucoma surgery: current implants and future innovations. Canadian Journal of Ophthalmology . 2014;49(6):528–533. doi: 10.1016/j.jcjo.2014.09.002. - DOI - PubMed
    1. Jones J., Koch D. D., Vold S., et al. Results from the United States cohort of the HORIZON trial of a Schlemm canal microstent to reduce intraocular pressure in primary open-angle glaucoma. Journal of Cataract & Refractive Surgery . 2019;45(9):1305–1315. doi: 10.1016/j.jcrs.2019.03.024. - DOI - PubMed
    1. Ivantis I. Hydrus microstent lowers visual field loss by 47% according to new 5-year pivotal trial data. 2021. https://www.prnewswire.com/news-releases/hydrus-microstent-lowers-visual... .

LinkOut - more resources